Considerations for Establishing Peptide Receptor Radionuclide Therapy: A Nationally Coordinated, Collaborative, and Equitable Service for New Zealand
Inspired by international frameworks, New Zealand established a nationally coordinated peptide receptor radionuclide therapy service. This article reflects on the key steps involved in building the service, including the formation of a national neuroendocrine tumor (NET) multidisciplinary meeting, the role of patient advocacy, and the integration of local research. The successful creation of the service, despite significant challenges, demonstrates the value of collaboration between clinicians, government, universities, and patient groups in achieving equitable, high-quality care.
Authors
- Trish Mead
- Jeff Davidson
- Andrew Henderson (ORCID: https://orcid.org/0000-0001-8216-1729)
- Mary Pat Sullivan (ORCID: https://orcid.org/0000-0001-9514-0783)
- Veronica Boyle (ORCID: https://orcid.org/0000-0003-3967-5200)
- Dragan Damianovich
- Lisa S. Meredith (ORCID: https://orcid.org/0000-0003-4523-7098)
- Avril Hull
- Ben Lawrence (ORCID: https://orcid.org/0000-0002-4358-4910)
- Rachelle Steyn
- Katherine Wells (ORCID: https://orcid.org/0009-0000-8318-4877)
- Tame Hauraki
- Yasmin Rennie
- Saskia Simmers
Institutions
- University of Auckland (NZ)
- Auckland City Hospital (NZ)
- Cancer Society of New Zealand (NZ)
- Mercy Angiography Unit (NZ)
Publication Details
- Journal
- World Journal of Nuclear Medicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1055/s-0045-1807726
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35